Les Nouvelles Esthetics & Spa

FEBRUARY 29, 2024

Additionally, automated communication tools keep clients engaged and informed throughout their treatment journey, improving satisfaction and loyalty. This seamless integration of technology ensures that every aspect of the client experience is considered and optimized, from the initial consultation to post-treatment care.

Innovations 78

Innovations Management Client Safety Client Care 78

The Dermatology Digest

APRIL 16, 2024

Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Market Access at Teva, in a news release.

Partnerships 74

Partnerships Injections Safety Marketing 74

The Dermatology Digest

DECEMBER 3, 2024

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

Marketing 36

Marketing Eczema Safety Management 36

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. immunology market.” “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb).

Portfolios 68

Portfolios Injections Office Safety 68

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

NOVEMBER 14, 2024

Regulatory filings in other markets are underway. We are incredibly excited to introduce a new topical treatment option to adult Swiss patients living with this debilitating disease as soon as possible.” The cream is fast-tracked by the U.S.

Marketing 36

Marketing Eczema Safety Innovations 36

AAAMS

NOVEMBER 13, 2024

These treatments are a natural fit for dental practices that focus on facial aesthetics, as they can complement smile makeovers, helping patients achieve a youthful, refreshed appearance that extends beyond their teeth. Botox®) and dermal fillers, as part of their cosmetic dentistry offerings.

Injections 52

Injections Training Facials Surgery 52

AAAMS

DECEMBER 16, 2024

Patients today seek treatments that offer impressive results with minimal downtime, making these procedures a must-know for practitioners aiming to stay ahead of the curve. Why Non-Surgical Treatments Are on the Rise Non-surgical cosmetic procedures are transforming the landscape of aesthetic medicine.

Chemical Peels 52

Chemical Peels Microneedling Social Media Surgery 52

The Dermatology Digest

DECEMBER 4, 2024

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Restem’s umbilical cord outer lining stem cells (ULSCs) program for the treatment of dermatomyositis (DM) and polymyositis (PM). The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals. PHOTO CREDIT: DermNet The post U.S.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections 68

Injections Medical Portfolios Branding 68

AAAMS

DECEMBER 19, 2024

Heres why it appeals to so many medical professionals: High Demand: Patients are increasingly seeking non-invasive cosmetic treatments, creating a steady demand for trained practitioners. Understanding patient safety protocols and treatment planning. Aesthetic medicine is one of the fastest-growing fields in healthcare.

Social Media 52

Social Media Work-Life Balance Training Microneedling 52

The Dermatology Digest

APRIL 23, 2024

Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to Abeona’s Biologics License Application (BLA) for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB).

Marketing 36

Marketing Safety Clinic Sustainability 36

The Beauty Brains

MAY 13, 2019

The Beauty Brains episode 182 – we cover beauty questions about BB glow facials The safety of self tanners Doing you own research and Hard water and your beauty products Beauty Science News Butt Masks Is natural deodorant necessary ? So, with the uncertain safety profile and the limited benefit I’m not sure I can recommend doing this.

Safety 40

Safety Facials Injections Ingredients 40

The Dermatology Digest

FEBRUARY 26, 2024

Sonelokimab is a novel investigational nanobody for the treatment of inflammatory disease. Marketing Authorization Application. European Medicines Agency (EMA) have greenlighted MoonLake Immunotherapeutics’ Phase 3 Program for the nanobody sonelokimab (SLK) in hidradenitis suppurativa (HS).

Office 74

Office Clinic Safety Innovations 74

Aesthetic Advancements Institute (AAI)

OCTOBER 18, 2023

Enter Percutaneous Collagen Induction (PCI) – a transformative treatment that’s catching the eyes of dermatologists and patients alike. microneedling market has seen a consistent upward trajectory since 2020, translating to more informed and effective treatments by practitioners. With Acne being a prime concern, the U.S.

Scarring 36

Scarring Microneedling Treatments Collagen 36

The Dermatology Digest

FEBRUARY 8, 2024

Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Maxine Drake

OCTOBER 27, 2023

Each day, you strive to provide your clients with exceptional experiences that leave them feeling incredibly happy with the results of products and treatments. This information forms the basis for creating personalized treatment plans. Impeccable Hygiene and Safety Hygiene and safety are non-negotiable in our industry.

Esthetics 52

Esthetics Customer Service Safety Consultation 52

NIMA Institute

JUNE 30, 2023

As the demand for non-surgical cosmetic treatments like Botox and dermal fillers continues to rise, the need for skilled professionals who can administer these procedures safely and effectively is greater than ever. Safety and Ethical Practices: Nima places a strong emphasis on safety and ethical practices in Botox and filler administration.

Training 52

Training Medical Esthetics Ethics Esthetics 52

The Dermatology Digest

MARCH 22, 2024

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS.

Rosacea 64

Rosacea Document Safety Ingredients 64

Spa Executive

JULY 17, 2024

Offering a full spectrum of services, from design and brand development to recruiting, marketing, and day-to-day operations, Arch Amenities Group transforms key areas into activated, profitable spaces. This adaptability is ideal for residential spas seeking to optimize their treatment offerings while catering to varying client needs.

Technology 98

Technology Hospital Sustainability Innovations 98

The Dermatology Digest

FEBRUARY 27, 2024

While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. “Biosimilars create opportunities for cost savings across the healthcare system and introduce additional treatment options for patients. Both Alvotech and Teva expect to launch SIMLANDI in the U.S. today, nearly 88% of U.S.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Lipgloss and Aftershave

OCTOBER 30, 2024

Unlike large laser companies that spend millions on marketing with big events, influencer partnerships, and doctor endorsements, we avoid these costly strategies, which often contribute to significant price markups. Question Which of your lasers offers a “pain-free” experience for the client?

Hair Removal 52

Hair Removal Skin Types Technology Safety 52

The Dermatology Digest

JUNE 14, 2024

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD. ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

SEPTEMBER 30, 2024

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. This marks the fourth FDA-approved biosimilar for Stelara. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

California Skincare Supply

OCTOBER 14, 2021

Compared to other trending treatments, microdermabrasion remains a cost-friendly option that continues to attract clients and produce consistent results. This post is part of a 4-part series on trending “micro” facial treatments. How many microdermabrasion treatments are advised?

Microdermabrasion 52

Microdermabrasion Exfoliation Chemical Peels Esthetician 52

AAAMS

MAY 9, 2024

Aesthetic nurse training has its roots in the evolution of nursing roles and the growing demand for specialized aesthetic treatments. This led to the development of specialized aesthetic nurse training programs that teach nurses how to administer injectables, perform laser treatments, and provide skincare services.

Training 52

Training Technology Ethics Injections 52

The Dermatology Digest

JULY 22, 2024

“Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

MAY 23, 2024

Food and Drug Administration accepted for review the supplemental biologics license application for bimekizumab-bkzx for the treatment of adults with moderate-to-severe HS. Other regulatory submissions for bimekizumab-bkzx in the treatment of moderate-to-severe hidradenitis suppurativa are underway around the world.

Sustainability 36

Sustainability Safety Clinic Medical 36

West Lake Dermatology

JANUARY 30, 2024

The market has seen a surge in at-home laser hair removal devices offering users the convenience of performing the treatment in the comfort of their homes. Safety should always be a top priority when considering any form of laser treatment. Professional laser hair removal achieves 95%+ hair removal within 7-9 sessions.

Hair Removal 36

Hair Removal Safety Technology Waxing 36

The Dermatology Digest

FEBRUARY 13, 2024

MediWound Ltd’s EscharEx bested market leader collagenase Santyl ointment in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU). The incidence of complete debridement during the daily treatment period (the first two weeks of the study) was 63.0% (95% CI=47.5-76.8)

Safety 36

Safety Marketing Office Clinic 36

Style Seat - Business Growth

JULY 23, 2024

Consider your target market as well. Understanding your target audience will help you tailor your services, pricing, and marketing strategies to attract and retain clients. Develop a comprehensive business plan With your spa concept and target market in mind, it’s time to create a detailed business plan.

Customer Service 40

Customer Service Legal Sanitation Marketing 40

California Skincare Supply

OCTOBER 14, 2021

Compared to other trending treatments, microdermabrasion remains a cost-friendly option that continues to attract clients and produce consistent results. This post is part of a 4-part series on trending “micro” facial treatments. Here is what estheticians, dermatologists, and plastic surgeons need to know.

Microdermabrasion 52

Microdermabrasion Exfoliation Chemical Peels Dermabrasion 52

The Dermatology Digest

JULY 10, 2024

The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

MARCH 11, 2024

Food and Drug Administration (FDA) recently accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

Texas Dermatology

DECEMBER 24, 2024

This non-invasive treatment uses advanced laser technology to target hair follicles, reducing regrowth and delivering lasting results. It is the most advanced laser technology on the market that can safely treat skin types I-VI. Proper training and expertise are crucial to ensure your safety and the best possible results.

Hair Removal 36

Hair Removal Waxing Moisturization Med Spa 36